| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal. TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | atezolizumab (Tecentriq®) |
| Formulation | 1200 mg concentrate for solution for infusion |
| Reference number | 4064 |
| Indication | In combination with bevacizumab, paclitaxel and carboplatin, for first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/04/2019 |
| NICE guidance | TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |